Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Patients

NCT06813339

Status	RECRUITING
Phase	Early Phase 1
Sponsor	Cyclarity Therapeutics, Inc.
Enrollment	84 participants

Key Eligibility Criteria

Inclusion (7)

- (Healthy Participants (SAD and MAD cohorts)):
- Healthy adult males and females, 18 to 55 years of age (inclusive) at the time of screening.
- Medically healthy with relevant renal parameters tests not exceeding 1.5 X the upper limits and no clinically significant screening results (e.g., laboratory profiles, medical history, vital signs, ECGs, physical examination) as deemed by the Principal Investigator; one retest is permitted at investigator discretion.
- (Participants with ACS (MD Patient cohort):
- Adult males and females, 40 to 79 years of age (inclusive) at the time of screening, diagnosed with acute coronary syndrome (ACS), at least 12 months post event (NSTEMI or unstable angina).

... and 2 more (see full listing online)

Exclusion (17)

- (Healthy Participants (SAD and MAD cohorts)):
- History or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease as deemed by the Principal Investigator.
- History of myocardial infarction (MI), transient ischemic attack (TIA), stroke, or familial history of coronary artery disease or first-degree heart attack below the age of 60.
- Any clinically significant ECG abnormality at Screening
- Diabetic participants

... and 12 more (see full listing online)

Locations (1 total)

CMAX Clinical Research, Adelaide, South Australia, Australia